In fact, phase I clinical studies assessing the efficiency of inhibitors of MPS1, a master regulator of the SAC, and of KIF18A, a kinesin-like motor protein that regulates chromosome positioning during cell division, are currently being conducted to treat a variety of cancer types (NCT02366949, NCT04293094). Here, TTK is linked to cancer.